Navigation Links
Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
Date:8/5/2008

NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, announced today that company representatives are giving three presentations at two conferences this week.

Gordon Research Conference on Medicinal Chemistry, August 3-8

Ashoke Bhattacharjee, Ph.D, Senior Scientist, presented at the Gordon Research Conference on Medicinal Chemistry this week at Colby Sawyer College, New London, NH. Dr. Bhattacharjee introduced Rib-X's enhanced macrolide program in a poster session titled, "Structure-Based Drug Design Targeting Infectious Disease: Overcoming Resistance and Extending the Antimicrobial Spectrum of Macrolide Antibiotics." In his presentation on August 3 and 4, Dr. Bhattacharjee highlighted how the combination of structural insights from X-ray crystallographic studies of known and new antibiotics bound to the bacterial 50S ribosomal subunit with data-driven computational chemistry tools allows for a fresh look at macrolide antibiotics.

Additionally, Graham Johnson, Ph.D, Chief Research Officer of Rib-X will give a presentation in the "Late-Breaking Topics" session, Thursday, August 7. The title of the talk is "Discovery and Clinical Development of radezolid (RX-1741), a Designer Oxazolidinone" and will highlight the company's proprietary discovery process utilizing structural, computational and chemistry approaches; radezolid has distinct physical properties as well as a promising efficacy and safety profile.

Drug Discovery & Development of Innovative Therapeutics World Conference, August 4-7

Joseph DeVito, Ph.D, Associate Director, Discovery Biology, Rib-X Pharmaceuticals, Inc., is presenting Rib-X's RX-04 program at IBC's 12th Annual Drug Discovery & Development of Innovative Therapeutics World Conference Technology Conference today at 11:00 AM ET at The World Trade Center Boston and Seaport Hotel, Boston, MA. Dr. DeVito will highlight RX-04 in a presentation titled "Using Structure-Based Discovery to Define Novel Antibiotics Targeting the 50S Ribosomal Subunit." RX-04 is Rib-X's de novo design of three completely new series of antibacterials showing promising activity against serious multidrug resistant Gram-negative pathogens, including, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Klebsiella pneumoniae, Acinetobacter baumanii and Escherichia coli.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in the fundamental process of protein synthesis. Many known, commercially valuable antibiotics bind to the ribosome, including those used to treat both community-acquired and hospital-acquired pathogens. The Company's integrated research strategy, which combines state of the art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotic classes. The Company currently has two programs in human clinical trials, the radezolid (RX-1741) designer oxazolidinone program as an oral/IV agent to treat serious hospital Gram-positive infections and the delafloxacin, (RX-3341) program, a next generation fluoroquinolone, active against a broad spectrum of bacteria, including methicillin-resistant Staphylococcus aureus. Additionally, the Company has multiple drug discovery programs. The first of these is a rapidly developing discovery program that has identified a new chemical classes of antibiotics active against multi-drug resistant Gram negative bacteria in the hospital. The second of these programs is focused on design and development of an IV and orally active macrolide for treatment of infections in the nursing home and hospital setting, including those caused by MRSA and enterococci.

For more information on the ribosome and the Rib-X mission, please visit the Company website at http://www.rib-x.com.


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
4. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
5. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
6. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
9. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
10. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
11. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Bio-Ess Laboratories, LLC Chief Science Officer, Dr. Adam Elhofy ... data on Cell-Ess® Universal Titer Boost at the 9 th ... August 21-25.  The Bioprocessing Summit convenes more than 1,000 international bioprocess ... ... Cell-Ess ...
(Date:8/15/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO), is now ... residents. Naloxone is available without a ... pharmacy, G-3320 Beecher Road. ... Administration, is intended to block or reverse the effects ... of consciousness. The medication is often carried by first ...
(Date:8/15/2017)... N.C. , Aug. 15, 2017 AccuGenomics, ... NC , today announced that the company has ... the University of North Carolina at Chapel Hill and ... is designed to characterize and quantify HIV reservoir and ... after pharmacological intervention. The HIV Cure Center is a ...
Breaking Medicine Technology:
(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult ... If so, you may be interested in participating in a research study that ... research is to understand more about the relational aspects of adults who have gluten ...
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... ... announced that it is the first organization with pending recognition status from the ... Prevention Program (“DPP”) via group telehealth classes and live video conferencing. , ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners of America ... as an interventional pain management physician. He brings a wealth of pain management ... headaches, and significant experience in spinal cord stimulation for chronic pain. , Dr. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... specialized asset-light logistics provider of complex transport solutions for mission-critical and non-discretionary ... Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. (NYSE: RRTS). ...
(Date:8/18/2017)... ... ... The Dawn Johnson Insurance Group, a Missouri-based insurance and financial planning firm ... for efforts to educate the local population on cancer realities while attracting donations to ... , Each day in America, roughly 4,600 new cases of cancer are diagnosed and ...
Breaking Medicine News(10 mins):